GM‐CSF secreted by B cells activates myeloid cells that worsen experimental disease, whilst GM‐CSF and IL6 secreting B cells are more abundant in MS and are at least in part ablated by anti‐B cell therapy and indicate a successful response to therapy (5, 30). This evidence concerns the gene IL6 and myeloid sarcoma.